Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study

Next Previous
Trial Profile

Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BEYOND III/FPG GOAL; FPG GOAL
  • Sponsors Sanofi

Most Recent Events

  • 16 Apr 2022 Results of post hoc analysis assessing extent and risk of factors of residual hyperglycaemia published in the Advances in Therapy.
  • 10 Nov 2021 Primary endpoint has been met (Percentage of patients with HbA1c 7% achievement) , according to results published in the Advances in Therapy
  • 10 Nov 2021 Results of post-hoc analysis assessing relationship between glycemic variability and fasting plasma glucose targets used to achieve glycated hemoglobin and HbA1c levels after 24 weeks of treatment with insulin glargine and oral antidiabetic drugs published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top